Literature DB >> 12161092

Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy.

Johan Wallin1, Jian-Guo Cui, Vadim Yakhnitsa, Gastón Schechtmann, Björn A Meyerson, Bengt Linderoth.   

Abstract

Spinal cord stimulation (SCS) is an effective tool in alleviating neuropathic pain. However, a number of well-selected patients fail to obtain satisfactory pain relief. Previous studies have demonstrated that i.t. baclofen and/or adenosine can enhance the SCS effect, but this combined therapy has been shown to be useful in less than half of the cases and more effective substances are therefore needed. The aim of this experimental study in rats was to examine whether gabapentin or pregabalin attenuates tactile allodynia following partial sciatic nerve injury and whether subeffective doses of these drugs can potentiate the effects of SCS in rats which do not respond to SCS. Mononeuropathy was produced by a photochemically induced ischaemic lesion of the sciatic nerve. Tactile withdrawal thresholds were assessed with von Frey filaments. Effects of increasing doses of gabapentin and pregabalin (i.t. and i.v.) on the withdrawal thresholds were analysed. These drugs were found to reduce tactile allodynia in a dose-dependent manner. In SCS non-responding rats, i.e. where stimulation per se failed to suppress allodynia, a combination of SCS and subeffective doses of the drugs markedly attenuated allodynia. In subsequent acute experiments, extracellular recordings from wide dynamic range neurones in the dorsal horn showed prominent hyperexcitability. The combination of SCS and gabapentin, at the same subeffective dose, clearly enhanced suppression of this hyperexcitability. In conclusion, electrical therapy and pharmacological therapy in neuropathic pain can, when they are inefficient individually, become effective when combined. Copyright 2002 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161092     DOI: 10.1053/eujp.2002.0329

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  16 in total

Review 1.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  James E Frampton; Rachel H Foster
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury.

Authors:  Lei Ding; Jie Cai; Xiang-Yang Guo; Xiu-Li Meng; Guo-Gang Xing
Journal:  Pain Res Manag       Date:  2014-05-21       Impact factor: 3.037

3.  [Effectiveness and time to onset of pregabalin in patients with neuropathic pain].

Authors:  R Freynhagen; P Busche; C Konrad; M Balkenohl
Journal:  Schmerz       Date:  2006-08       Impact factor: 1.107

4.  Systemic pregabalin attenuates sensorimotor responses and medullary glutamate release in inflammatory tooth pain model.

Authors:  N Narita; N Kumar; P S Cherkas; C Y Chiang; J O Dostrovsky; T J Coderre; B J Sessle
Journal:  Neuroscience       Date:  2012-05-17       Impact factor: 3.590

5.  Venlafaxine compromises the antinociceptive actions of gabapentin in rat models of neuropathic and persistent pain.

Authors:  Frederik Rode; Tine Broløs; Gordon Blackburn-Munro; Ole J Bjerrum
Journal:  Psychopharmacology (Berl)       Date:  2006-06-17       Impact factor: 4.530

Review 6.  Pregabalin: in the treatment of painful diabetic peripheral neuropathy.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Evidence that pregabalin reduces neuropathic pain by inhibiting the spinal release of glutamate.

Authors:  Naresh Kumar; Andre Laferriere; Jonathan S C Yu; Amelia Leavitt; Terence J Coderre
Journal:  J Neurochem       Date:  2010-01-28       Impact factor: 5.372

Review 8.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  Kate McKeage; Susan J Keam
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  Pregabalin suppresses nociceptive behavior and central sensitization in a rat trigeminal neuropathic pain model.

Authors:  Ye Cao; Hua Wang; Chen-Yu Chiang; Jonathan O Dostrovsky; Barry J Sessle
Journal:  J Pain       Date:  2013-02       Impact factor: 5.820

Review 10.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.